  [{"2025-04-02T08:44:00-04:00": {
    "datetime": "2025-04-02T08:44:00-04:00",
    "tittle": "Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership",
    "summary": "NEW BRUNSWICK, N.J., April 02, 2025--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine.",
    "url": "https://finnhub.io/api/news?id=e990279925aac6c7adc63c98e031af112f42befe3d1569ac48ded58d8dd414bc",
    "source": "Yahoo",
    "related": "JNJ",
    "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
    "category": "company"
  },
    "2025-03-26T08:03:00-04:00": {
    "datetime": "2025-03-26T08:03:00-04:00",
    "tittle": "New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9 in San Diego, California.",
    "url": "https://finnhub.io/api/news?id=166d60ffe3b17a87acfe3371104d36a6f20eececace0cf78ede1695812f52854",
    "source": "Yahoo",
    "related": "JNJ",
    "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
    "category": "company"
  },
  "2025-03-26T15:40:11-04:00": {
    "datetime": "2025-03-26T15:40:11-04:00",
    "tittle": "Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off",
    "summary": "We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors often […]",
    "url": "https://finnhub.io/api/news?id=d1b87fd9d1607fcb0d7ebfd9c5dfb7bc04f5bd29a4bcf64b01c0fd8aeab54363",
    "source": "Yahoo",
    "related": "JNJ",
    "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
    "category": "company"
  },
  "2025-03-27T10:13:04-04:00": {
    "datetime": "2025-03-27T10:13:04-04:00",
    "tittle": "How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain",
    "summary": "Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a \"wait-and-see\" pattern.",
    "url": "https://finnhub.io/api/news?id=6ddb50eb5b3605adb9a4f9ae65a9a63fbfee3e28e700e07ecba34a73a219e00b",
    "source": "Yahoo",
    "related": "JNJ",
    "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
    "category": "company"
  },
  "2025-03-26T09:40:10-04:00": {
    "datetime": "2025-03-26T09:40:10-04:00",
    "tittle": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=044da3b2d7cf3fd7d2abd605ab510c43cc86e0f5c03ee0dac248804e732ca3d4",
    "source": "Yahoo",
    "related": "JNJ",
    "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
    "category": "company"
  },
  "2025-03-29T09:54:41-04:00": {
    "datetime": "2025-03-29T09:54:41-04:00",
    "tittle": "Jim Cramer on Johnson & Johnson (NYSE:JNJ): Their Spinoff Was Ill-Advised",
    "summary": "We recently published a list of Jim Cramer Says Trump’s Tariff Strategy Is Working & Discusses These 11 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer […]",
    "url": "https://finnhub.io/api/news?id=1e11e09f12f40c631daf42e22e27828d787719019aea571909e7ce4921732ad5",
    "source": "Yahoo",
    "related": "JNJ",
    "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
    "category": "company"
  }
}]